The CDC ended its Biobot contract in 2023 and replaced it with Verily/WastewaterSCAN, reducing one major federal customer relationship.
SourcePopulation health analytics powered by wastewater.
Public company, workplace, funding, and market signals
Biobot Analytics is a Cambridge-based, MIT-born wastewater intelligence company that turns sewage samples into privacy-first, population-level public health and biosecurity insights for governments, healthcare systems, and life-sciences customers.
Primary product
Wastewater intelligence platform (Biobot Advance and related dashboards/API services)
Founded
2017
Headquarters
Cambridge, Massachusetts, United States
Team size
20-30 employees
Work style
Flexible
Industry
Data Infrastructure and Analytics
Sub-industry
Wastewater epidemiology / public health intelligence
Offices
0 jobs at Biobot Analytics
Check back later for new openings
Business model
Stage
Venture-backed / growth
Total raised
$91.5M
Latest round
Venture Round · Jun 2025
Leadership
CEO & Cofounder
President & Cofounder
Chief Revenue Officer
Chief Product Officer
Vice President Marketing
Mission-driven, science-heavy, and privacy-first; combines biology, urban/public-health research, data science, and engineering; emphasizes community trust, real-time response, and interdisciplinary problem solving.
Work style
Flexible
Compensation
No official public salary band was found. Public career aggregators and job listings indicate equity, strong benefits, and role-specific pay signals around the mid-$90k range for associate data science roles and around the mid-$140k range for staff engineer roles, plus a 3% 401(k) contribution and other perks.
Benefits
Pricing
Quote-based, custom contract pricing / annual service agreements; public reporting suggests municipal engagements can start around $15k per year.
Differentiators
Technology
Customers
Competitors
Estimated revenue
$20M-$30M
Estimated monthly visits
5.4K
Traffic estimate as of Jul 2026
The CDC ended its Biobot contract in 2023 and replaced it with Verily/WastewaterSCAN, reducing one major federal customer relationship.
SourceMassachusetts is ending its wastewater surveillance contract with Biobot on July 31, 2026, and will move the work in-house.
SourceA broader market shift toward state in-house surveillance programs is reducing reliance on vendors like Biobot in some regions.
SourceThe Boston Globe · Jul 2026
The Commonwealth of Massachusetts is ending its contract with Biobot on July 31, 2026; the article also notes the CDC ended its contract in 2023 and that Biobot still works with dozens of communities and agencies.
PR Newswire / Biobot Analytics · Jun 2026
Biobot published Nature Water findings showing that near-real-time wastewater intelligence can predict substance-use trends at national scale and led fatal-overdose reporting by 15 months.
PR Newswire / Biobot Analytics · Jan 2026
Biobot won an ONDCP contract to provide nationwide insight on more than 20 chemical targets, extending its federal substance-use monitoring work.
PR Newswire / Biobot Analytics · Jun 2025
Biobot announced a new funding round led by Valor Equity Partners, with Atreides Management joining and Hyperplane participating.
Biobot Analytics · Apr 2024
Biobot and Mathematica reported that wastewater data can detect emerging opioid threats, predict overdoses, and help tailor treatment and program decisions.